Fabio Mioli joins the PHSE Group today. As of 1 January 2025, he will assume the role of head of PHSE International, the Group’s sub-holding in which all foreign activities are concentrated, reporting directly to Eddy De Vita, Executive President of PHSE Group. Fabio Mioli assumes this responsibility from Graham Inglis, who has reorganised and developed the Group’s International business since 2020, and who will continue to lead this business until 31 December 2024, thus enabling an organized transition.
Fabio Mioli brings to the Group a wealth of experience in the Life Sciences Healthcare sector, having occupied senior roles in the commercial, strategic, purchasing, operations and supply chain areas for both pharmaceutical companies (Wyeth Pharmaceuticals, Schering-Plough and Procter Gamble) and service companies (such as Alliance Boots, DHL Supply Chain and UPS Healthcare, where he held the positions of Commercial Affairs Dir. GM, BU Director of Hospital, Specialty Pharma, Medical Devices and Country Manager Healthcare South Europe).
“Fabio’s appointment represents an exciting development for PHSE International. In this new position, he will be responsible for driving our growth in Europe, America and Asia, both organically and through strategic acquisitions. This is work already started by Graham Inglis, whom I would very much like to thank”, commented Eddy De Vita, Executive President of the company.
Since joining the business, Graham Inglis has contributed to the Group’s overall development, as well as growing the foreign business and delivering important results for PHSE International. Achievements include the rationalisation of the UK, US and Singapore branches, the opening of the Spanish hub, the three acquisitions in the UK, India and Brazil; and, further acquisitions, already at an advanced stage of development, are likely to follow in the coming months. Graham Inglis will remain as a member of the Board of Directors of PHSE, and will continue to support the strategic development of the Group.
The turnover of the Group, one of the world’s leading players in temperature-controlled Healthcare transport and last-mile distribution, has more than tripled in four years, rising from around € 27 million in 2019 to around € 86 million in 2023 (cagr +33%) also thanks to the completion of five acquisitions, three of which abroad (UK, India and Brazil) and two in Italy. These acquisitions have supported the development of new services for customers, including direct-to-patient, ground and air transport of radiopharmaceuticals and cell gene therapies, and strengthened the Group’s international capabilities.
